Ascendis Pharma A/SASNDNASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank54
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$-113.90M
↑ 57% vs avg
Percentile
P54
Within normal range
Streak
3 yr
Consecutive growthExpanding
Average
$-265.93M
Historical baseline
PeriodValueYoY Change
2025$-113.90M+60.7%
2024$-290.02M+29.5%
2023$-411.17M+22.3%
2022$-529.18M-45.1%
2021$-364.64M+10.6%
2020$-407.81M-93.9%
2019$-210.36M-40.1%
2018$-150.18M-36.7%
2017$-109.88M-52.4%
2016$-72.12M-